Key result
Specific ATTR-CM therapy was associated with a significant 19% reduction in troponin I at 2 years alongside stable eGFR and imaging biomarkers.
Why the study?
Does specific ATTR-CM therapy (tafamidis or acoramidis) stabilize or improve laboratory and imaging biomarkers at 1- and 2-year follow-up in patients with transthyretin amyloid cardiomyopathy?
Cohort (n=43)
No
Does specific ATTR-CM therapy (tafamidis or acoramidis) stabilize or improve laboratory and imaging biomarkers at 1- and 2-year follow-up in patients with transthyretin amyloid cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In a real-world cohort of patients with ATTR-CM treated with specific therapy (primarily tafamidis), cardiac imaging parameters and renal function remained stable over 2 years while troponin I levels significantly decreased by 19%.
Trajectories of laboratory and imaging biomarkers in patients with treated amyloid transthyretin cardiomyopathy -real world data from the CroATTR registryConclusion: In this real-world cohort of patients treated with specific ATTR-CM therapy no significant change of imaging parameters was observed, NT-proBNP showed a trend of decrease, eGFR remained stable, and significantly lower TnI was observed at 2yFUP, while more than 50% of patients remained in the NAC stage I (Figure 1).
No takes yet. Share an insight, caveat, or question.
Planinc et al. (2026) conducted a cohort in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=43). Specific ATTR-CM therapy (tafamidis or acoramidis) vs. Baseline values was evaluated on Change in Troponin I at 2-year follow-up compared to baseline (Geometric mean ratio 0.81, 95% CI 0.69-0.94, p=0.008). Specific ATTR-CM therapy was associated with a significant 19% reduction in troponin I at 2 years alongside stable eGFR and imaging biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: